Tempus leverages best-in-class laboratories to provide a variety of next-generation sequencing (NGS) tests and targeted arrays to support testing needs from discovery through to commercialization.
Sequencing of bio-banked samples to identify molecular drivers in an early-phase clinical trial
Sequencing to support patient eligibility screening and molecular characterization of patients enrolled across later phase trial under a significant risk IDE
Analytical and clinical validation of multiple biomarkers under a NGS assay for pursuit of a companion diagnostic partnership
Read MoreTesting specific cohorts of patients to identify appropriate patients for targeted therapies in rare patient populations
Centralized sequencing, bioinformatics and common data standards for all of a pharmaceutical partner’s IITs (1,000+ patients enrolled in 10+ separate investigator-initiated trials)
200+
biopharma partners
95%
of the top 20 oncology pharma companies rely on Tempus*
~65%
of all Academic Medical Centers in the US are connected to Tempus
Tempus xT CDx*648 gene panel, tumor/normal matched for solid tumors, and two companion diagnostic (CDx) claims for colorectal cancer (CRC) patients
Learn more
- 500x median coverage of tumor samples
- 95% of exons at >150x coverage
- ≥98% of exons at ≥100x coverage
- SNVs, MNVs, insertions /deletions, MSI
Tempus xT648 gene panel, tumor/normal matched. Heme and solid tumors
May be ordered as a standalone assay or in combination with xR.
Download validation summary
Tempus xRWhole transcriptome RNA seq panel for solid tumors and hematologic malignancies
May be ordered as a standalone assay or in combination with xT.
Learn more
Tempus xF+523 gene liquid biopsy panel (114 gene enhanced region). Solid tumors
Tempus xEWhole exome, tumor/normal matched and whole transcriptome RNA-seq. Heme and solid tumors
Tempus xG/xG+52 or 88 gene panel, covers genes associated most common hereditary cancer types
Tempus xM MonitorctDNA Tumor Fraction Calculation & Monitoring
A ctDNA assay which measures changes in ctDNA tumor fraction to determine early response to immunotherapy for patients with advanced cancers. Currently available for research use only.
Learn moreTempus xM MRDMinimal Residual Disease Detection
Tumor-naïve minimal residual disease (MRD) liquid biopsy test that detects trace amounts of residual ctDNA in patients with stage II-III colorectal cancer.
Learn moreA comprehensive immunotherapy platform that provides actionable and cutting-edge services for life sciences partners advancing IO therapies, including antibody-drug conjugates (ADCs), TCR therapies, and immune checkpoint inhibitors (ICIs).
Learn moreTempus operates CAP-accredited, CLIA-certified robotic sequencing labs in Chicago, Atlanta, and Raleigh with automated bioinformatics and variant classification reporting. Sequencing is typically completed within a median of 8 days after receiving samples.
Download our lab overview
Tempus’ extensive suite of multi-omics offerings provides pharma partners with key datasets for a critical, integrated, and holistic understanding of their populations.
Learn more about multi-omicsGenotyping: Robust portfolio of solutions through Illumina & Thermo Fisher, offering solutions for data projects of all sizes
Methylation: Epigenetic & DNA methylation profiling from one of the highest throughput methylation labs in the US
Whole Genome, Exome & Transcriptome Sequencing: Powerful WGS, flexible WES and WTS, and cost-effective Low Pass WGS
Metagenomics: Microbiome analysis support through shotgun or 16s rRNA sequencing
Proteomics: Leading technologies with high-throughput capabilities, enabling precise biomarker discovery and expansive multi-omic analysis.
During this engaging session, you will: Examine the role novel biomarkers and combination treatment strategies play in understanding and enhancing the immune system's response to cancer; discover the significant developments that are helping to shape clinical trials and enhance patient outcomes in IO; and hear perspectives from industry experts on the potential of emerging therapies.
Register nowOne integrated solution for all phases of drug development
The largest multimodal database library of more than 6 million de-identified research records to support novel biomarker discovery, hypothesis validation, and late stage clinical trial design.
Learn moreAn intuitive and comprehensive multi-modal data platform that powers new insights across the R&D spectrum, helping pharma make smarter decisions and launch molecules more efficiently.
Learn moreEmpowers pharma partners with access to bioinformatics experts to help answer research questions comprehensively and reach objectives efficiently.
Learn moreOther Solutions for Life Sciences
Contact us today.